Literature DB >> 23070776

Flow cytometry-based cell type-specific assessment of target regulation by pulmonary siRNA delivery.

Olivia M Merkel1, Leigh M Marsh, Holger Garn, Thomas Kissel.   

Abstract

Pulmonary siRNA delivery has attracted strong interest and has been reported to successfully mediate target gene knockdown in a number of disease models. However, the nature of the epithelial cells that eventually take up siRNA and the question if other lung cell types may also be transfected have so far been neglected. Therefore, we describe here a flow cytometry-based method using transgenic enhanced green fluorescence protein-expressing mice (EGFP mice) for the differentiation of transfected lung cell populations based on their antigen expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23070776      PMCID: PMC3841064          DOI: 10.1007/978-1-62703-140-0_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  The silent treatment: siRNAs as small molecule drugs.

Authors:  D M Dykxhoorn; D Palliser; J Lieberman
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

Review 2.  In vivo animal models for drug delivery across the lung mucosal barrier.

Authors:  Sally-Ann Cryan; Neeraj Sivadas; Lucila Garcia-Contreras
Journal:  Adv Drug Deliv Rev       Date:  2007-08-31       Impact factor: 15.470

3.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.

Authors:  Kenneth A Howard; Ulrik L Rahbek; Xiudong Liu; Christian K Damgaard; Sys Zoffmann Glud; Morten Ø Andersen; Mads B Hovgaard; Alexander Schmitz; Jens R Nyengaard; Flemming Besenbacher; Jørgen Kjems
Journal:  Mol Ther       Date:  2006-07-10       Impact factor: 11.454

4.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

5.  Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium.

Authors:  S Ferrari; C Kitson; R Farley; R Steel; C Marriott; D A Parkins; M Scarpa; B Wainwright; M J Evans; W H Colledge; D M Geddes; E W Alton
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

6.  Identification of transfected cell types following non-viral gene transfer to the murine lung.

Authors:  Lee A Davies; Claire Seguela; Anusha Varathalingam; Seng H Cheng; Stephen C Hyde; Deborah R Gill
Journal:  J Gene Med       Date:  2007-03       Impact factor: 4.565

7.  Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins.

Authors:  J Rosenecker; S Naundorf; S W Gersting; R W Hauck; A Gessner; P Nicklaus; R H Müller; C Rudolph
Journal:  J Gene Med       Date:  2003-01       Impact factor: 4.565

8.  Isolation and primary culture of murine alveolar type II cells.

Authors:  M Corti; A R Brody; J H Harrison
Journal:  Am J Respir Cell Mol Biol       Date:  1996-04       Impact factor: 6.914

9.  Functional polarity is introduced by Dicer processing of short substrate RNAs.

Authors:  Scott D Rose; Dong-Ho Kim; Mohammed Amarzguioui; Jeremy D Heidel; Michael A Collingwood; Mark E Davis; John J Rossi; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

Review 10.  Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.

Authors:  Günter Oberdörster; Eva Oberdörster; Jan Oberdörster
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

View more
  5 in total

1.  Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.

Authors:  Panagiotis Mastorakos; Adriana L da Silva; Jane Chisholm; Eric Song; Won Kyu Choi; Michael P Boyle; Marcelo M Morales; Justin Hanes; Jung Soo Suk
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 2.  siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?

Authors:  Aditi Mehta; Thomas Michler; Olivia M Merkel
Journal:  Adv Healthc Mater       Date:  2021-01-27       Impact factor: 11.092

3.  Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.

Authors:  Domizia Baldassi; Shubhankar Ambike; Martin Feuerherd; Cho-Chin Cheng; David J Peeler; Daniel P Feldmann; Diana Leidy Porras-Gonzalez; Xin Wei; Lea-Adriana Keller; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Andreas Popp; Gerald Burgstaller; Suzie H Pun; Thomas Michler; Olivia M Merkel
Journal:  J Control Release       Date:  2022-03-29       Impact factor: 11.467

4.  Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma.

Authors:  Yuran Xie; Na Hyung Kim; Venkatareddy Nadithe; Dana Schalk; Archana Thakur; Ayşe Kılıç; Lawrence G Lum; David J P Bassett; Olivia M Merkel
Journal:  J Control Release       Date:  2016-03-19       Impact factor: 9.776

5.  Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.

Authors:  Qian Zhong; Olivia M Merkel; Joshua J Reineke; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-05-13       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.